Platelet biology and receptor pathways

Journal of Cardiovascular Translational Research

Volumn 6, Issue 3, 2013, Pages 299-309

  Cimmino, Giovanni ^a   Golino, Paolo ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Aggregation; Coagulation; Membrane receptors; Platelet

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALX 0081; ANTICOAGULANT AGENT; ATOPAXAR; CLOPIDOGREL; COLLAGEN RECEPTOR ANTAGONIST; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN VI ANTAGONIST; GLYCOPROTEINIB ANTIBODY; INTEGRIN; INTEGRIN ALPHA2BETA1 ANTAGONIST; MICRORNA; MONOCLONAL ANTIBODY JAQ1; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN SYNTHASE; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; PURINERGIC RECEPTOR; THROMBOCYTE RECEPTOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; TIROFIBAN; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 2; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR ANTIBODY; VORAPAXAR;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BINDING AFFINITY; BLEEDING; BLEEDING DISORDER; BLOOD CLOTTING; BLOOD VISCOSITY; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CELL GRANULE; CYTOLOGY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOTHELIUM INJURY; ENZYME ACTIVITY; GENE FUNCTION; HEALING; HEMOSTASIS; HUMAN; IMMUNITY; INFLAMMATION; ISCHEMIA; LYSOSOME; MACROPHAGE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RETICULOENDOTHELIAL SYSTEM; RISK REDUCTION; RNA SPLICING; RNA TRANSLATION; SHEAR STRESS; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; THROMBOCYTE RELEASE REACTION; THROMBOCYTE STRUCTURE; THROMBOCYTE VOLUME; THROMBOSIS; THROMBOSIS PREVENTION; TRANSCRIPTION REGULATION; VASCULAR ENDOTHELIUM;

ANIMALS; BLOOD PLATELETS; HEMOSTASIS; HUMANS; MICRORNAS; PLATELET ACTIVATION; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 84877742479     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-012-9445-9     Document Type: Article

References (83)

1. Jurk, K., & Kehrel, B. E. (2005). Platelets: Physiology and biochemistry. Seminars in Thrombosis and Hemostasis, 31(4), 381-392.
2. Schulze, H., & Shivdasani, R. A. (2005). Mechanisms of thrombopoiesis. Journal of Thrombosis and Haemostasis, 3(8), 1717-1724.
3. Rendu, F., & Brohard-Bohn, B. (2001). The platelet release reaction: Granules' constituents, secretion and functions. Platelets, 12, 261-273.
4. Escolar, G., & White, J. G. (1991). The platelet open canalicular system: A final common pathway. Blood Cells, 17, 467-485.
5. Fox, J. E. (1993). The platelet cytoskeleton. Thrombosis and Haemostasis, 70, 884-893.
6. McNicol, A., & Israels, S. J. (1999). Platelet dense granules: Structure, function and implications for haemostasis. Thrombosis Research, 95, 1-18.
7. Heijnen, H. F., Debili, N., Vainchencker, W., Breton-Gorius, J., Geuze, H. J., & Sixma, J. J. (1998). Multivesicular bodies are an intermediate stage in the formation of platelet alpha-granules. Blood, 91(7), 2313-2325.
8. Harrison, P., & Cramer, E. M. (1993). Platelet alpha-granules. Blood Reviews, 7, 52-62.
9. Semple, J. W., Italiano, J. E., Jr., & Freedman, J. (2011). Platelets and the immune continuum. Nature Reviews Immunology, 11(4), 264-274.
10. Angiolillo, D. J., Ueno, M., & Goto, S. (2010). Basic principles of platelet biology and clinical implications. Circulation Journal, 74, 597-607.
11. Varga-Szabo, D., Pleines, I., & Nieswandt, B. (2008). Cell adhesion mechanisms in platelets. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 403-412.
12. Kroll, M. H., Hellums, J. D., McIntire, L. V., Schafer, A. I., & Moake, J. L. (1996). Platelets and shear stress. Blood, 88, 1525-1541.
13. Ballerman, B. J., Dardik, A., Eng, E., & Liu, A. (1998). Shear stress and the endothelium. Kidney International. Supplement, 67, S100-S108.
14. Ikeda, Y., Handa, M., Kawano, K., Kamata, T., Murata, M., Araki, Y., et al. (1991). The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. The Journal of Clinical Investigation, 87(4), 1234-1240.
15. Lisman, T., Raynal, N., Groeneveld, D., Maddox, B., Peachey, A. R., Huizinga, E. G., et al. (2006). A single high-affinity binding site for von Willebrand Factor in collagen III, identified using synthetic triple-helical peptides. Blood, 108, 3753-3756.
16. Kumar, R. A., Dong, J. F., Thaggard, J. A., Cruz, M. A., Lopez, J. A., & McIntire, L. V. (2003). Kinetics of GPIb alpha-vWF-A1 tether bond under flow: Effect of GPIb alpha mutations on the association and dissociation rates. Biophysical Journal, 85, 4099-4109.
17. Savage, B., Almus-Jacobs, F., & Ruggeri, Z. M. (1998). Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell, 94, 657-666.
18. Van de Walle, G. R., Vanhoorelbeke, K., Majer, Z., Illyes, E., Baert, J., Pareyn, I., et al. (2005). Two functional active conformations of the integrin alpha 2 beta 1, depending on activation condition and cell type. Journal of Biological Chemistry, 280, 36873-36882.
19. Nieswandt, B., & Watson, S. P. (2003). Platelet-collagen interaction: Is GPVI the central receptor? Blood, 102, 449-461.
20. Dale, G. L., Friese, P., Batar, P., et al. (2002). Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature, 415, 175-179.
21. Coller, B. S., Scudder, L. E., Beer, J., Gold, H. K., Folts, J. D., Cavagnaro, J., et al. (1991). Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Annals of the New York Academy of Sciences, 614, 193-213.
22. Madan, M., Berkowitz, S. D., & Tcheng, J. E. (1998). Glycoprotein IIb/IIIa integrin blockade. Circulation, 98, 2629-2635.
23. Linkoff, A. M., Califf, R. M., & Topol, E. J. (2000). Platelet glycoprotein blockade in coronary artery disease. Journal of the American College of Cardiology, 35, 1103-1115.
24. Anderson, K. M., Califf, R. M., Stone, G. W., Nemann, F.-J., Montalescot, G., Miller, D. P., et al. (2001). Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. Journal of the American College of Cardiology, 37, 2059-2065.
25. Offermanns, S. (2006). Activation of platelet function through G protein coupled receptors. Circulation Research, 99, 1293-1304.
26. Abbracchio, M. P., Burnstock, G., Boeynaems, J. M., Barnard, E. A., Boyer, J. L., Kennedy, C., et al. (2006). International Union of Pharmacology LVIII: Update on the P2Y G protein-coupled nucleotide receptors: From molecular mechanisms and pathophysiology to therapy. Pharmacological Reviews, 58, 281-341.
27. Ohlmann, P., Castro, S., Brown, G. G., Jr., Gachet, C., Jacobson, K. A., & Harden, T. K. (2010). Quantification of recombinant and platelet P2Y(1) receptors utilizing a [(125)I]-labeled high-affinity antagonist 2-iodo-N(6)-methyl-(N)-methanocarba-2′-deoxyadenosine-3′, 5′-bisphosphate ([(125)I]MRS2500). Pharmacological Research, 62(4), 344-351.
28. 1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. Journal of Biological Chemistry, 273(4), 2030-2034.
29. 1 purinoceptor in ADP-induced platelet activation. FEBS Letters, 422(3), 291-295.
30. 2 formation is prevented. Journal of Thrombosis and Haemostasis, 2(6), 969-977.
31. 12 receptors at the level of calcium signaling in human platelets. Blood, 104(6), 1745-1752.
32. Yang, J., Wu, J., Jiang, H., Mortensen, R., Austin, S., Manning, D. R., et al. (2002). Signaling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors. Journal of Biological Chemistry, 277(48), 46035-46042.
33. Martin, V., Guillermet-Guibert, J., Chicanne, G., Cabou, C., Jandrot-Perrus, M., Plantavid, M., et al. (2010). Deletion of the p110beta isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. Blood, 115(10), 2008-2013.
34. Hirsch, E., Bosco, O., Tropel, P., Laffargue, M., Calvez, R., Altruda, F., et al. (2001). Resistance to thromboembolism in PI3Kgamma-deficient mice. The FASEB Journal, 15(11), 2019-2021.
35. Jin, J., & Kunapuli, S. P. (1998). Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proceedings National Academy Science USA, 95(14), 8070-8074.
36. 12 receptor antagonist AR-C69931MX but not aspirin. Thrombosis and Haemostasis, 88, 488-494.
37. FitzGerald, G. A. (1991). Mechanisms of platelet activation: Thromboxane A2 as an amplifying signal for other agonists. The American Journal of Cardiology, 68, 11B-15B.
38. Coughlin, S. R. (1999). How the protease thrombin talks to cells. Proceedings of the National Academy of Sciences of the United States of America, 96, 11023-7.
39. Ossovskaya, V. S., & Bunnett, N. W. (2004). Protease-activated receptors: Contribution to physiology and disease. Physiological Reviews, 84, 579-621.
40. Vu, T. K., Hung, D. T., Wheaton, VI, & Coughlin, S. R. (1991). Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell, 64, 1057-1068.
41. O'Brien, P. J., Molino, M., Kahn, M., & Brass, L. F. (2001). Protease activated receptors: Theme and variations. Oncogene, 20, 1570-1581.
42. Kahn, M. L., Nakanishi-Matsui, M., Shapiro, M. J., Ishihara, H., & Coughlin, S. R. (1999). Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. The Journal of Clinical Investigation, 103, 879-887.
43. Steinhoff, M., Buddenkotte, J., Shpacovitch, V., Rattenholl, A., Moormann, C., Vergnolle, N., et al. (2005). Proteinase-activated receptors: Transducers of proteinase-mediated signaling in inflammation and immune response. Endocrine Reviews, 26, 1-43.
44. Shapiro, M. J., Weiss, E. J., Faruqi, T. R., & Coughlin, S. R. (2000). Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. Journal of Biological Chemistry, 275, 25216-25221.
45. Newman, P. J., Gorski, J., & White, G. C., 2nd. (1988). Enzymatic amplification of platelet-specific messenger RNA using the polymerase chain reaction. The Journal of Clinical Investigation, 82, 739-743.
46. Gnatenko, D. V., Dunn, J. J., & McCorkle, S. R. (2003). Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood, 101, 2285-2293.
47. Kieffer, N., Guichard, J., & Farcet, J. P. (1987). Biosynthesis of major platelet proteins in human blood platelets. European Journal of Biochemistry, 164, 189-195.
48. Weyrich, A. S., Lindemann, S., & Tolley, N. D. (2004). Change in protein phenotype without a nucleus: Translational control in platelets. Seminars in Thrombosis and Hemostasis, 30, 491-498.
49. Healy, A. M., Pickard, M. D., & Pradhan, A. D. (2006). Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation, 113, 2278-2284.
50. Denis, M. M., Tolley, N. D., & Bunting, M. (2005). Escaping the nuclear confines: Signal-dependent pre-mRNA splicing in anucleate platelets. Cell, 122, 379-391.
51. Schwertz, H., Tolley, N. D., & Foulks, J. M. (2006). Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets. The Journal of Experimental Medicine, 203, 2433-2440.
52. Baek, D., Villen, J., & Shin, C. (2008). Nature, 455, 64-71.
53. Small, E.M., Frost, R.J., Olson, E.N. (2010). MicroRNAs add a new dimension to cardiovascular disease. Circulation, 121, 1022-1032.
54. Landry, P., Plante, I., & Ouellet, D. L. (2009). Existence of a microRNA pathway in anucleate platelets. Nature Structural and Molecular Biology, 16(9), 961-966.
55. Cimmino, G., Tarallo, R., Nassa, G., De Filippo, M.R., Conte, S., Pellegrino, G., Morello, A., Cirillo, P., Weisz, A., Golino, P. (2012). Activation modulates miRNA expression profile in platelets: New insights into the pathophysiology of platelet activation. AHA Scientific Session, Abstract 12998
56. 12 platelet inhibition in clinical practice. Journal of Thrombosis and Thrombolysis, 33(2), 143-153.
57. Chamorro, A. (2009). TP receptor antagonism: A new concept in atherothrombosis and stroke prevention. Cerebrovascular Diseases, 27(Suppl 3), 20-27. Epub 2009 May 14.
58. Nieswandt, B., Schulte, V., Bergmeier, W., Mokhtari-Nejad, R., Rackebrandt, K., Cazenave, J. P., et al. (2001). Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. The Journal of Experimental Medicine, 193, 459-469.
59. Li, H., Lockyer, S., Concepcion, A., Gong, X., Takizawa, H., Guertin, M., et al. (2007). The Fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 1199-1205.
60. Massberg, S., Konrad, I., Bültmann, A., Schulz, C., Münch, G., Peluso, M., et al. (2004). Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. The FASEB Journal, 18, 397-399.
61. Ungerer, M., Rosport, K., Bültmann, A., Piechatzek, R., Uhland, K., Schlieper, P., et al. (2011). Novel antiplatelet drug revacept (dimeric glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation, 123, 1891-1899.
62. Vanhoorelbeke, K., Ulrichts, H., Schoolmeester, A., & Deckmyn, H. (2003). Inhibition of platelet adhesion to collagen as a new target for antithrombotic drugs. Current Drug Targets. Cardiovascular & Haematological Disorders, 3, 125-140.
63. Van Bockstaele, F., Holz, J. B., & Revets, H. (2009). The development of nanobodies for therapeutic applications. Current Opinion in Investigational Drugs, 10(11), 1212-1224.
64. ClinicalTrials.gov. (2009). Comparative study of ALX-0081 versus GPIIb/IIIa inhibitor in high risk percutaneous coronary intervention (PCI) patients. Retrieved from http://clinicaltrials.gov/ct2/show/record/NCT01020383.
65. Tricoci, P., Huang, Z., Held, C., Moliterno, D. J., Armstrong, P. W., Van de Werf, F., et al. (2012). Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. The New England Journal of Medicine, 366(1), 20-33. Epub 2011 Nov 13.
66. Morrow, D. A., Braunwald, E., Bonaca, M. P., Ameriso, S. F., Dalby, A. J., Fish, M. P., et al. (2012). Vorapaxar in the secondary prevention of atherothrombotic events. The New England Journal of Medicine, 366(15), 1404-1413.
67. Morrow, D. A., Scirica, B. M., Fox, K. A., Berman, G., Strony, J., Veltri, E., et al. (2009). Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. American Heart Journal, 158(335-341), e333.
68. Warner, T. D., & Mitchell, J. A. (2004). Cyclooxygenases: New forms, new inhibitors, and lessons from the clinic. The FASEB Journal, 18, 790-804.
69. Smith, W. L., & Langenbach, R. (2001). Why there are two cyclooxygenase isozymes. The Journal of Clinical Investigation, 107(12), 1491-1495.
70. Chandrasekharan, N. V., Dai, H., Roos, L. T., Evanson, N. K., Tomsik, J., Elton, T. S., et al. (2002). COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proceedings of the National Academy of Sciences of the United States of America, 99(21), 13926-13931.
71. Dubois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., Van De Putte, L. B., et al. (1998). Cyclooxygenase in biology and disease. The FASEB Journal, 12(12), 1063-1073.
72. Xie, W., Chipman, J. G., Roberston, D. L., Erikson, R. L., & Simmons, D. L. (1991). Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proceedings of the National Academy of Sciences of the United States of America, 88(7), 2682-2686.
73. Smith, W. L., & DeWitt, D. L. (1995). Biochemistry of prostaglandin endoperoxide H synthase and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Seminars in Nephrology, 15, 179-194.
74. Kulmacz, R. J., & Wang, L. H. (1995). Comparison of hydroperoxide initiator requirements for the cyclooxygenase activities of prostaglandin H synthase-1 and -2. Journal of Biological Chemistry, 270, 24019.
75. Smyth, S. S., Mcever, R. P., Weyrich, A. S., Morrell, C. N., Hoffman, M. R., Arepally, G. M., et al. (2009). Platelet functions beyond hemostasis. Journal of Thrombosis and Haemostasis, 7, 1759-1766.
76. Li, C., Li, J., Li, Y., Lang, S., Yougbare, I., Zhu, G., et al. (2012). Crosstalk between platelets and the immune system: Old systems with new discoveries. Advances in Hematology, 2012, 384685. Epub 2012 Sep 12.
77. Aslam, R., Speck, E. R., Kim, M., et al. (2006). Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-α production in vivo. Blood, 107(2), 637-641.
78. Littman, D. R., & Rudensky, A. Y. (2010). Th17 and regulatory T cells in mediating and restraining inflammation. Cell, 140(6), 845-858.
79. Austrup, F., Vestweber, D., Borges, E., et al. (1997). P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflamed tissues. Nature, 385(6611), 81-83.
80. Elzey, B. D., Tian, J., Jensen, R. J., et al. (2003). Platelet-mediated modulation of adaptive immunity: A communication link between innate and adaptive immune compartments. Immunity, 19(1), 9-19.
81. Kopp, H. G., Placke, T., & Salih, H. R. (2009). Platelet-derived transforming growth factor-β down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Research, 69(19), 7775-7783.
82. Baenziger, N. L., Brodie, G. N., & Majerus, P. W. (1971). A thrombin-sensitive protein of human platelet membranes. Proceedings of the National Academy of Sciences of the United States of America, 68(1), 240-243.
83. Crawford, S. E., Stellmach, V., Murphy-Ullrich, J. E., et al. (1998). Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell, 93(7), 1159-1170.